UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________________ Commission File Number: 000- 55347 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its c ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - CEO Cedric O'Gorman - Chief Medical Officer Maged Shenouda - CFO Conference Call Participants Rudy Li - Leerink Partner Andrea Tan - Goldman Sachs Operator Greetings, and welcome to Relmada Therapeutics Inc. Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It's now my p ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________________ Commission File Number: 000 - 55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its chart ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - Chief Executive Officer Cedric O'Gorman - Chief Medical Officer Maged Shenouda - Maged Shenouda Conference Call Participants Rudy Li - SVB Securities Uy Ear - Mizuho Andrew Tsai - Jefferies Andrea Tan - Goldman Sachs Yatin Suneja - Guggenheim Partners Operator Good afternoon. Thank you for attending today's Relmada Therapeutics Inc. First Qu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________________ to ___________________________ Commission File Number: 000-55347 RELMADA THERAPEUTICS, INC. (Exact name of registrant as specified in its charte ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors Sergio Traversa - CEO Maged Shenouda - CFO Cedric O'Gorman - Chief Medical Officer Conference Call Participants Uy Ear - Mizuho Health Guofang Li - SVB Securities Andrea Tan - Goldman Sachs Andrew Tsai - Jefferies Jay Olson - Oppenheimer Operator Greetings and welcome to Relmada Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call. [Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Commission file number: 000-55347 Relmada Therapeutics, Inc. (Exact name of registrant as specified in its charter) Nevada 45-5401931 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identi ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Maurizio Fava - Chairman, Harvard Psychiatry Department Conference Call Participants Guofang Li - SVB Securities Uy Ear - Mizuho Yatin Suneja - Guggenheim Partners Andrea Tan - Goldman Sachs Andrew Tsai - Jefferies Jay Olson - Oppenheimer Joon Lee - Truist Securities Oper ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Brian Ritchie - LifeSci Advisors Sergio Traversa - Chief Executive Officer John Hixon - Head of Commercial Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Yatin Suneja - Guggenheim Andrea Tan - Goldman Sachs Joon Lee - Truist Securities Jay Olson - Oppenheimer Uy Ear - Mizuho Securities Operator Good day, ladies and gentlemen, and welcome to ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisors, Investor Relations Sergio Traversa - Chief Executive Officer Maged Shenouda - Chief Financial Officer Conference Call Participants Andrew Tsai - Jefferies Andrea Tan - Goldman Sachs Yatin Suneja - Guggenheim Partners Marc Goodman - SVB Leerink Vamil Divan - Mizuho Securities Matt Hershenhorn - Oppenheimer Operator Ladies and gentlemen, thank you for standing ...